-
- Posted Monday September 1, 2008
TGen and Washington University Researchers Discover New Approach to Treating Endometrial Cancer
Inhibitor turns "off" receptors; stops the growth of endometrial tumors and kills cancer cells
PHOENIX, Ariz. - Sept. 1, 2008 - Researchers at the Translational Genomics Research Institute (TGen) today announced a new approach to treating endometrial cancer patients that not only stops the growth of tumors, but kills the cancer cells.
In a potentially major breakthrough, TGen scientists and collaborators at Washington University School of Medicine in St. Louis discovered that introducing a particular inhibitor drug can turn "off" receptors responsible for the growth of tumors in a significant number of patients with endometrial cancer.
And, they found that the inhibitor drug proved effective even in cancer tumors containing a commonly occurring mutant gene, PTEN, previously associated with resistance to drug treatment.
TGen's findings appear today in a paper published as a priority report by Cancer Research, a Philadelphia-based peer-reviewed journal dedicated to original cancer research.
A clinical trial based on the TGen study will start within the next year. Dr. Pamela Pollock, an associate investigator in TGen's Cancer and Cell Biology Division and the paper's senior author, led a team that used the latest genome-scanning technology to sequence 116 endometrioid endometrial tumor samples. This work was done in association with Dr. Paul Goodfellow, an expert in endometrial cancer and a professor in the departments of Surgery and of Obstetrics and Gynecology at Washington University.
Pollock and colleagues in May 2007 announced that they had discovered previously unrecognized alterations in the fibroblast growth factor receptor 2 (FGFR2) gene. The altered FGFR2 is present in the cancer cells of nearly 15 percent of women with endometrioid endometrial tumors. These kinds of tumors represent 80 percent of all endometrial cancers.
By introducing a commercially available inhibitor drug, PD173074, TGen researchers showed that they could stop the growth of tumors, and even kill cancer cells, in cases where the tumors contained the altered FGFR2 gene. The altered gene causes the receptors to get stuck in the "on" position and signal the endometrial cells to grow out of control.
"These findings could accelerate the development of new treatments for endometrial cancer because there are already drugs in clinical trials that inhibit FGFR2 function," Pollock said.
Current treatment of endometrial cancer can involve surgical removal of the uterus, radiation and chemotherapy. While many women are successfully treated with these approaches, about 15 percent of those with endometrioid endometrial cancer have persistent or recurring tumors that are resistant to current drug therapies. Mutations in several genes previously have been identified in endometrial tumors, but they have not been suitable drug targets - until now.
"This targeted approach holds great promise for patients with uterine cancer (endometrioid endometrial) tumors that contain the FGFR2 mutation," said TGen physician-in-chief, Dr. Daniel Von Hoff, "and offers yet another powerful example of how genomic medicine is changing the way we look at and treat cancer."
Goodfellow agreed, "The discovery that endometrial cancer cells die when treated with an FGFR2 inhibitor - even when they carry other genetic abnormalities common in uterine cancers - suggests anti-FGFR2 therapies have great potential."
The researchers' already established ties with the National Cancer Institute, which will assist with the clinical trials, should speed the development of new therapies, Goodfellow said. "Our collaborative group's strong ties with the NCI's Gynecologic Oncology Group will allow us to rapidly take our findings from the lab to patients."
Endometrial cancer, which invades the inner wall of the uterus, is the most common gynecological cancer in the United States. This year more than 40,000 women will be diagnosed and nearly 7,500 women will die of the disease, according to the American Cancer Society (ACS).
Among women, only breast, lung and colon cancers strike with more frequency. And while endometrial cancer is slow to develop, and often is not detected until after age 60, nearly one in eight women who are diagnosed die within five years, according to the ACS.
Pollock plans to start clinical trials with an FGFR inhibitor in endometrial cancer patients within a year. The trials will be conducted in collaboration with Dr. Matthew Powell, a gynecologic oncologist and assistant professor of Obstetrics and Gynecology at Washington University School of Medicine.
Targeted drug therapy is a relatively new approach to cancer treatment that is based on identifying the abnormalities in cancer cells that cause them to grow uncontrollably. It involves treating tumors with drugs that specifically inhibit the activity of these genetic abnormalities.
This approach of targeted therapy allows oncologists to match the therapy to the specific genetic signature of each patient's tumor, a strategy that has been effective in multiple cancer types, including breast cancer, lung cancer and chronic myelogenous leukemia.
TGen's Clinical Research Services (TCRS) at Scottsdale Healthcare Shea in Scottsdale, Ariz., is enrolling women with gynecological cancers into several related clinical trials. The aim is to provide patients with personalized medicine, targeting drug treatments tailored to their individual needs.
A comprehensive listing of TCRS clinical trials can be found at www.tgen.org. Click on Research, Clinical Research and then Clinical Trials.
The study was funded, in part, by a two-year, $100,000 ($50,000 per year) grant from the Cary, N.C.-based, V Foundation for Cancer Research. The foundation is named in remembrance of famed North Carolina State basketball coach and award-winning broadcaster Jimmy Valvano, a cancer research advocate who died of Metastatic Adenocarcinoma in 1993.
# # #
About TGen
The Translational Genomics Research Institute (TGen) is a
non-profit organization dedicated to conducting groundbreaking
research with life changing results. Research at TGen is focused on
helping patients with diseases such as cancer, neurological
disorders and diabetes. TGen is on the cutting edge of
translational research where investigators are able to unravel the
genetic components of common and complex diseases. Working with
collaborators in the scientific and medical communities, TGen
believes it can make a substantial contribution to the efficiency
and effectiveness of the translational process.
About Washington University School of Medicine
Washington University School of Medicine's 2,100 employed and
volunteer faculty physicians also are the medical staff of
Barnes-Jewish and St. Louis Children's hospitals. The School of
Medicine is one of the leading medical research, teaching and
patient care institutions in the nation, currently ranked third in
the nation by U.S. News & World Report. Through its
affiliations with Barnes-Jewish and St. Louis Children's hospitals,
the School of Medicine is linked to BJC HealthCare. Visit:
medschool.wustl.edu.
Press Contacts:
TGen
Galen Perry
AVP Marketing and Communications
602-343-8423
[email protected]
Gwen Ericson
Assistant Director of Research Communication
Medical Public Affairs
Washington University, St. Louis, Mo.
314-286-0141
[email protected]
